Skip to main content

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Written by Customer Service on . Posted in Public Companies.

Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets

Science, 3 July 2025

Molecular Glue Computational mining expands the target space for induced-proximity drugs
Molecular Glue Computational mining expands the target space for induced-proximity drugs

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries featured on the cover of Science. The research article, “Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition,” details how Monte Rosa’s proprietary artificial intelligence (AI) and machine learning (ML) engine has uncovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes. These findings dramatically expand the actionable target space for MGD drug discovery.

“The findings from this landmark publication, featured on the cover of Science, have accelerated our ability to develop first-in-class medicines for historically intractable targets, validating the power of our QuEEN™ discovery engine to create the next generation of molecular glue degrader medicines,” said Sharon Townson, Ph.D., Chief Scientific Officer of Monte Rosa. “We’re already leveraging these insights to advance our growing pipeline of differentiated MGDs and future medicines that have the potential to transform patients’ lives.”

“Our cutting-edge approach to MGD discovery integrates internal datasets with geometric deep learning to characterize protein surfaces. We have uncovered new rules of engagement between protein targets, small molecules and E3 ligases such as cereblon that we’re actively exploiting via our proprietary QuEEN discovery engine to rationally design exquisitely selective degrader therapies,” said John Castle, Ph.D., Chief Data and Information Officer at Monte Rosa. “This work not only highlights the flexibility of cereblon but also demonstrates our ability to design MGDs that address previously inaccessible, disease-relevant proteins.”

Monte Rosa’s QuEEN discovery engine uses custom-built AI/ML algorithms to analyze protein surfaces at unprecedented scale, identifying previously unrecognized surfaces capable of recruiting cereblon for targeted protein degradation. The novel surface features greatly expand the reach of MGDs and redefine the requirements that govern molecular glue-induced target engagement. The paper further details Monte Rosa’s proprietary AI and ML approaches that enabled these discoveries, incorporating geometric deep learning to encode protein surface patches and project geometrical features across the proteome to identify complementary structures that can mediate protein-protein interactions. The analysis successfully identified new protein targets amenable to Monte Rosa’s drug discovery approach, spanning more than 100 target classes, many of which are currently considered to be inaccessible to small molecule binding. The findings significantly broaden Monte Rosa’s potential therapeutic reach in areas including immunology, inflammation and oncology, where the company is currently advancing programs in the clinic.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1f1f3cc5-631e-4162-a50f-cdbdc3ee864b

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.